EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease

Maximilian Wolf, Julian Lange, Dirk Benndorf, Lina Welz, Susanna Nikolaus, Laura Katharina Siever, Florian Tran, Kay Schallert, Patrick Hellwig, Stefan Schreiber, Matthias Gunzer, Philip Rosenstiel und 5 weitere

Journal of Proteomics · 2025

DOI: 10.1016/j.jprot.2025.105455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Proteomics, 2025. Verfasst von Maximilian Wolf und 16 weiteren Autor:innen. Beteiligte Einrichtung: Multidimensional Omics Analyses group, Faculty of Technology, Bielefeld University, Universitätsstrasse 25, 33615 Bielefeld, Germany; Graduate School…. Hauptthemen laut MEDLINE: Feces, Inflammatory Bowel Diseases, Gastrointestinal Microbiome, Proteomics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Else Kröner-Fresenius-Stiftung, Federal Ministry of Education and Research Bonn Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiome is an important contributor to the development and the course of inflammatory bowel disease (IBD). While changes in the gut microbiome composition were observed in response to IBD therapy using biologics, studies elucidating human and microbial proteins and pathways in dependence on therapy success are sparse. Fecal samples of a cohort of IBD patients were collected before and after 14 weeks of treatment with three different biologics. Clinical disease activity scores were used to determine the clinical response and remission. Fecal metaproteomes of remitting patients (n = 12) and of non-remitting patients (n = 12) were compared before treatment and changes within both groups were assessed over sampling time to identify functional changes and potential human and microbial biomarkers. The abundance of proteins associated with neutrophilic granulocytes, and immunoglobulins significantly decreased in remitting patients. There were changes in pathways of microbial metabolism in samples from patients with remission after therapy, including an increased butyrate fermentation. Distinct changes of proteins related to gut inflammation and gut microbiome metabolism showed whether IBD remission was achieved or not. This suggests that metaproteomics could be a useful tool for monitoring remission in IBD therapies. SIGNIFICANCE: IBD is rising in incidence, especially in newly industrialized countries, and the microbiome is an important contributor to its pathogenesis. Despite manifold therapeutical options, achieving remission is often ineffective, and choosing new alternative drugs remains often empirical. Therefore, efficient tools for monitoring therapeutic response and assessing the effectiveness of drugs in specific patients are mandatory. In the present study, we show that the use of metaproteomics is a promising avenue to address these challenges. We observed the amelioration of inflammation and restoration of a healthy microbiome in remitting patients in contrast to non-remitting patients. Therefore, metaproteomics is a valuable tool for monitoring the therapy success in IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FecesInflammatory Bowel DiseasesGastrointestinal MicrobiomeProteomicsProteomeHumansFemaleMaleAdultMiddle AgedRemission InductionBiomarkers

Stichwörter der Autor:innen

Crohn's diseaseFecal samplesInflammatory bowel diseaseMetaproteomicsNon-invasive diagnosisUlcerative colitis

Substanzen

BiomarkersProteome

Autor:innen und Institutionen

  • Multidimensional Omics Analyses group, Faculty of Technology, Bielefeld University, Universitätsstrasse 25, 33615 Bielefeld, Germany; Graduate School DILS, Bielefeld Institute for Bioinformatics Infrastructure (BIBI), B…
  • Bioprocess Engineering, Otto-von-Guericke University Magdeburg, Universitätsplatz 2, 39106 Magdeburg, Germany.
  • Applied Biosciences and Process Engineering, Anhalt University of Applied Science, Bernburger Straße 56, 06366 Koethen, Germany.
  • Institute of Clinical Molecular Biology, Christian-Albrechts University of Kiel, Rosalind-Franklin-Straße 12, 24105 Kiel, Germany.
  • Leibniz-Institut für Analytische Wissenschaften - ISAS - e., Bunsen-Kirchhoff-Str. 11, 44139 Dortmund, Germany.
  • Bioprocess Engineering, Otto-von-Guericke University Magdeburg, Universitätsplatz 2, 39106 Magdeburg, Germany; Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstraße 1, 39106 Magdeburg, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Else Kröner-Fresenius-Stiftung
  • Federal Ministry of Education and Research Bonn Office

Zitieren

APA

Wolf, M., Lange, J., Benndorf, D., Welz, L., Nikolaus, S., Siever, L. K., Tran, F., Schallert, K., Hellwig, P., Schreiber, S., Gunzer, M., Rosenstiel, P., Reichl, U., Adolph, T., Jukic, A., Aden, K., & Heyer, R. (2025). Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease. Journal of Proteomics. https://doi.org/10.1016/j.jprot.2025.105455

Vancouver

Wolf M, Lange J, Benndorf D, Welz L, Nikolaus S, Siever LK, et al. Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease. Journal of Proteomics. 2025. doi:10.1016/j.jprot.2025.105455

BibTeX
@article{Wolf2025,
  author = {Wolf, Maximilian and Lange, Julian and Benndorf, Dirk and Welz, Lina and Nikolaus, Susanna and Siever, Laura Katharina and Tran, Florian and Schallert, Kay and Hellwig, Patrick and Schreiber, Stefan and Gunzer, Matthias and Rosenstiel, Philip and Reichl, Udo and Adolph, Timon and Jukic, Almina and Aden, Konrad and Heyer, Robert},
  title = {Fecal metaproteomics enables functional characterization of remission in patients with inflammatory bowel disease},
  journal = {Journal of Proteomics},
  year = {2025},
  doi = {10.1016/j.jprot.2025.105455}
}
Kostenlos starten →